Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and Biophytis (NASDAQ:BPTS – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Valuation and Earnings
This table compares Ascendis Pharma A/S and Biophytis’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ascendis Pharma A/S||$53.93 million||101.20||-$614.45 million||($11.30)||-8.38|
Biophytis has lower revenue, but higher earnings than Ascendis Pharma A/S.
|Net Margins||Return on Equity||Return on Assets|
|Ascendis Pharma A/S||-500.93%||-257.83%||-58.01%|
This is a breakdown of recent ratings for Ascendis Pharma A/S and Biophytis, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ascendis Pharma A/S||0||3||7||0||2.70|
Ascendis Pharma A/S presently has a consensus target price of $141.00, indicating a potential upside of 48.97%. Biophytis has a consensus target price of $15.00, indicating a potential upside of 1,896.54%. Given Biophytis’ stronger consensus rating and higher probable upside, analysts clearly believe Biophytis is more favorable than Ascendis Pharma A/S.
Volatility & Risk
Ascendis Pharma A/S has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Biophytis has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Biophytis beats Ascendis Pharma A/S on 7 of the 9 factors compared between the two stocks.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.